Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 12—December 2022

Acinetobacter baumannii among Patients Receiving Glucocorticoid Aerosol Therapy during Invasive Mechanical Ventilation, China

Wenchao Zhang1, Mei Yin1, Wei Li, Nana Xu, Haining Lu, Weidong Qin, Hui Han, Chen Li, Dawei Wu, and Hao WangComments to Author 
Author affiliations: Qilu Hospital of Shandong University, Jinan, China (W. Zhang, M. Yin, W. Li, N. Xu, W. Qin, H. Han, C. Li, H. Wang); Qingdao Branch, Qilu Hospital of Shandong University, Qingdao, China (H. Lu, D. Wu)

Cite This Article


CME Logo


In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Medscape, LLC designates this Journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 75% minimum passing score and complete the evaluation at; and (4) view/print certificate.

Release date: November 17, 2022; Expiration date: November 17, 2023
Learning Objectives

Upon completion of this activity, participants will be able to:

  • Distinguish the percentage of patients receiving invasive mechanical ventilation (IMV) who had a positive culture for Acinetobacter baumannii (AB)

  • Assess the role of aerosol inhalation in the isolation of AB in the current study

  • Analyze risk factors for the isolation of AB in the current study

  • Evaluate the effects of aerosol inhalation and AB on the risk for mortality among patients receiving IMV

CME Editor

Amy J. Guinn, BA, MA, Technical Writer/Editor, Emerging Infectious Diseases. Disclosure: Amy J. Guinn, BA, MA, has no relevant financial relationships.

CME Author

Charles P. Vega, MD, Health Sciences Clinical Professor of Family Medicine, University of California, Irvine School of Medicine, Irvine, California. Disclosure: Charles P. Vega, MD, has the following relevant financial relationships: served as an advisor or consultant for GlaxoSmithKline; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.


Wenchao Zhang, MD, PhD; Mei Yin, MD, PhD; Wei Li, MD, PhD; Nana Xu, MD; Haining Lu, MD; Weidong Qin, MD, PhD; Hui Han, MD; Chen Li, MD; Dawei Wu, MD; Hao Wang, MD, PhD.



Acinetobacter baumannii is a nosocomial pathogen associated with severe illness and death. Glucocorticoid aerosol is a common inhalation therapy in patients receiving invasive mechanical ventilation. We conducted a prospective cohort study to analyze the association between glucocorticoid aerosol therapy and A. baumannii isolation from ventilator patients in China. Of 497 enrolled patients, 262 (52.7%) received glucocorticoid aerosol, and A. baumannii was isolated from 159 (32.0%). Glucocorticoid aerosol therapy was an independent risk factor for A. baumannii isolation (hazard ratio 1.5, 95% CI 1.02–2.28; p = 0.038). Patients receiving glucocorticoid aerosol had a higher cumulative hazard for A. baumannii isolation and analysis showed that glucocorticoid aerosol therapy increased A. baumannii isolation in most subpopulations. Glucocorticoid aerosol was not a direct risk factor for 30-day mortality, but A. baumannii isolation was independently associated with 30-day mortality in ventilator patients. Physicians should consider potential A. baumannii infection when prescribing glucocorticoid aerosol therapy.

Acinetobacter baumannii, a gram-negative coccobacillus, is a major nosocomial pathogen worldwide. A. baumannii is particularly challenging in intensive care units (ICUs). According to the Extended Prevalence of Infection in Intensive Care study, aimed at providing information on the prevalence of infection in ICUs worldwide, Acinetobacter spp. constituted 8.8% of all culture-positive ICU infections in 2007 (1), which increased to 11.4% in 2017 (2). However, infection rates differed markedly, ranging from 1.0% in North America to 25.6% in Asia and the Middle East and 22.9% in eastern Europe (2). Patients on invasive mechanical ventilation are particularly vulnerable to A. baumannii infection and colonization due to airway barrier destruction and bacterial virulence factors such as motility, epithelial adherence, and biofilm formation that enable A. baumannii colonization in the airways (3,4). A. baumannii in patient airways is associated with longer hospitalization, higher medical expenses, and increased mortality rates (57). Identifying risk factors for A. baumannii infection is crucial for implementing preventive measures and decreasing overall illness and death.

Aerosol inhalation is widely used in patients requiring mechanical ventilation. Glucocorticoids are frequently administered during aerosol therapy, especially in China (810). Compared with systemic application, aerosol therapy has several advantages, including targeted delivery to the lungs, faster response, and fewer systemic side effects (11,12). However, the aerosols and droplets generated during aerosol inhalation can become sources of respiratory pathogens (13), and inhaled glucocorticoids might suppress pulmonary immunity (14), which could increase the opportunity for nosocomial acquisition. Inhaled corticosteroids are associated with an increased risk for pneumonia in patients with chronic obstructive pulmonary disease (COPD) (15). However, the effects of glucocorticoid aerosol inhalation on nosocomial infection risk has not been clearly elucidated.

Glucocorticoid aerosol therapy is mainly indicated for patients with asthma, COPD (16), acute respiratory distress syndrome (ARDS) (17), and some pathophysiological conditions, such as airway hyperresponsiveness (18), hyperinflammation, and mucosal edema (19). In the past decade, use of glucocorticoid aerosol therapy has increased in hospitals in China; on average, >40% of patients on mechanical ventilation receive this therapy (9). In addition, a market analysis determined that aerosolized glucocorticoid sales in China were almost 3-fold higher in 2018 than in 2012 (20).

Although epidemiology has demonstrated a slow increase in A. baumannii infection globally over the past decade (1,2), the increase in A. baumannii incidence in China appears to have outpaced increases in other regions worldwide (2123). According to the China Antimicrobial Surveillance Network (CHINET), a national surveillance of the trends of bacterial strains isolated from the major hospitals in China, the number of Acinetobacter spp. strains increased by 2.7-fold in 2018 compared with 2012 (23,24). Previously, we reported a marked increase in the incidence of A. baumannii–related bloodstream infections and incidence of pneumonia-related A. baumannii infections in ICUs in China that were 3.2-fold higher during 2017–2018 than during 2011–2012 (25). A. baumannii was the most frequent bacterial isolate in ventilator-associated pneumonia in China, and rates were 35.7%–52.7% (26,27). Furthermore, the incidence of the drug-resistant phenotype of A. baumannii is high. According to CHINET reports, carbapenem-resistant A. baumannii strains increased from 31% in 2005 to 66.7% in 2014 (28), then to ≈80% in 2018 (29). We previously reported that carbapenem resistance rates in ICUs in China increased from 25% during 2011–2012 to 95.7% during 2017–2018 (25). A multicenter study of ICUs in China reported that multidrug-resistant (MDR) A. baumannii was detected in 40% of all cases (30).

We hypothesized that increased use of glucocorticoid aerosol therapy might contribute to increased A. baumannii incidence. Therefore, we performed a prospective cohort study of critically ill patients receiving invasive mechanical ventilation in China to determine whether use of aerosolized glucocorticoid increased the risk for A. baumannii isolation.


Study Design and Patients

During January 2018–August 2019, we conducted a prospective cohort study at 3 adult ICUs in 2 hospitals in Shandong Province, China: Qilu Hospital of Shandong University in Jinan and Qingdao Branch of Qilu Hospital in Qingdao. We enrolled patients on their first day of invasive mechanical ventilation in the ICU and obtained written informed consent for all patients. We divided the patients into 3 groups on the basis of their treatment: no aerosol inhalation therapy, glucocorticoid aerosol therapy, and aerosol inhalation without glucocorticoid. Within 48 hours of patient enrollment, we collected secretion samples from the lower respiratory tract by transtracheal aspiration for microbial culture; thereafter, we collected samples 3 times per week until we obtained an A. baumannii–positive culture. We followed patients for 30 days after enrollment. If the patient was hospitalized for >3 weeks, we reduced the culture frequency to once a week. We excluded patients who received invasive mechanical ventilation for <48 hours; received aerosol inhalation or glucocorticoid aerosol for <48 hours after enrollment and before A. baumannii–positive culture; were <18 years of age; were assumed to have A. baumannii infection or colonization at baseline because they were A. baumannii–positive before enrollment or within the first 48 hours of enrollment; or had been exposed to >1 of the following A. baumannii risk factors before enrollment: antimicrobial drugs for >7 days, invasive mechanical ventilation for >5 days, or vasopressor for >3 days. We also excluded patients who lacked follow-up data or had incomplete information. The Institutional Ethics Committee of Qilu Hospital of Shandong University approved our study.


We performed microbial cultures according to standard procedures. In brief, we incubated respiratory samples on MacConkey agar plates at 5% CO2 and 35°C for 48 h. We identified A. baumannii, a gram-negative, nonfermentative, and oxidase-negative coccobacillus, by using the VITEK 2 compact system and GN ID card (bioMérieux, We used Escherichia coli (ATCC accession no. 25922) and Pseudomonas aeruginosa (ATCC accession no. 27853) as quality controls.

Definitions and Data Collection

We defined no aerosol inhalation as patients who did not receive aerosolized medications during the study. We defined glucocorticoid aerosol therapy as patients who received aerosolized glucocorticoids for >48 hours after enrollment and before A. baumannii isolation, with or without nonglucocorticoid aerosolized medications for any duration. We defined aerosol inhalation without glucocorticoid as patients who received only aerosolized nonglucocorticoid medications, such as bronchodilators and expectorants, for >48 hours after enrollment and before A. baumannii isolation. We excluded all other conditions.

The primary endpoint was A. baumannii isolation, which we defined as A. baumannii–positive culture from the lower respiratory tract samples collected during the ICU stay. Negative outcomes were no A. baumannii isolation before death, ICU discharge, or end of follow-up period. We recorded the time-to-event, which we defined as number of days from enrollment to A. baumannii isolation.

We collected baseline information at ICU admission, including age, sex, history of smoking and surgeries, underlying conditions, past inhaled steroids for chronic conditions, and Charlson comorbidity index. We used the Acute Physiology and Chronic Health Evaluation II (APACHE II) score to assess illness severity. We also recorded other possible A. baumannii risk factors, such as use of broad-spectrum antimicrobial drugs, invasive mechanical ventilation, urethral catheter placement, vasopressor treatment, renal dialysis, and length of ICU stay. In addition, we recorded indications for glucocorticoid aerosol therapy by reviewing patients’ medical records. We reviewed patients’ clinical data to determine A. baumannii isolation status as infection, colonization, or undefined.

Statistical Analyses

We expressed continuous variables as median and interquartile range (IQR) or mean and SD and categorical variables as number and percentage. We used univariate and multivariate Cox proportional hazards regression and hazard ratio (HR) and 95% CI to assess risk factors for A. baumannii isolation and 30-day mortality. We performed propensity score matching analysis to reduce the imbalance between the glucocorticoid aerosol therapy and nonglucocorticoid groups. We included all possible covariables (i.e., demographics, background history, underlying conditions, and disease severity) in the propensity score matching. We calculated propensity scores by using a logistic regression model. We applied a 1:1 nearest neighbor matching algorithm with a caliper of 0.02 and without replacement. We assessed balance of variables in both groups by standardized differences. We analyzed A. baumannii isolation in complete cases and the propensity-matched cohort. We used Kaplan-Meier curves to visually compare cumulative hazards for A. baumannii isolation among the 3 groups, which we evaluated by using a log-rank test. To assess the consistency of glucocorticoid therapy in terms of its effect on A. baumannii isolation from prespecified subgroups with different characteristics, we applied Cox proportional hazards model with Efron’s method for handling ties and used forest plots for HRs and 95% CIs. We assessed heterogeneity of efficacy of glucocorticoid therapy on A. baumannii isolation in subgroups by using an interaction test, expressed p values for interaction, and considered p<0.05 statistically significant. We performed all analyses by using SPSS Statistics 16.0 (IBM, and R version 3.0 (R Foundation for Statistical Computing,


Participant Characteristics

We enrolled 671 patients from 3 ICUs and excluded 174 patients. The final cohort consisted of 497 patients: 137 (27.6%) received no aerosol inhalation, 262 (52.7%) received glucocorticoid aerosol, and 98 (19.7%) received aerosol inhalation without glucocorticoid (Figure 1). We isolated A. baumannii from 159 (32.0%) patients. The median patient age was 60.1 (IQR 49–73) years, and 67.8% were male. The median length of ICU stay was 15 (IQR 7–23) days. Besides A. baumannii, the 3 other bacteria commonly isolated were Klebsiella pneumoniae (n = 38, 7.6%), P. aeruginosa (n = 27, 5.4%), and E. coli (n = 15, 3.0%) (Appendix Table 1). Most (22.5%) study patients received glucocorticoid therapy for ARDS and for asthma or COPD (21.3%) (Appendix Table 2).

Risk Factors for A. baumannii Isolation

We performed univariate Cox regression analysis of risk factors for A. baumannii isolation (Table 1). Compared with no aerosol inhalation, glucocorticoid aerosol therapy had a statistically significant effect on A. baumannii isolation (HR 1.860, 95% CI 1.264–2.738; p = 0.002). Aerosol inhalation without glucocorticoid was not a risk factor for A. baumannii (p>0.05). Other candidate risk factors were cardiovascular diseases, chronic renal insufficiency, COPD or asthma, current or former smoking history, use of broad-spectrum antimicrobial drugs for >7 days, invasive mechanical ventilation for >5 days, vasopressor treatment, renal dialysis for >3 days, and APACHE II score.

To assess whether glucocorticoid aerosol therapy was an independent risk factor for A. baumannii isolation, we established 2 models using multivariate Cox regression analysis in complete cases. Model 1 included all variables, and model 2 only included variables with p<0.1 in the univariate analysis. Glucocorticoid aerosol was an independent risk factor for A. baumannii isolation in both model 1 (HR 1.499, 95% CI 1.001–2.246; p = 0.049) (Appendix Table 3) and model 2 (HR 1.528, 95% CI 1.024–2.278; p = 0.038) (Table 2). Cardiovascular diseases, prolonged use of broad-spectrum antimicrobial drugs, invasive mechanical ventilation, and vasopressor treatment were other independent risk factors for A. baumannii (Table 2; Appendix Table 3). As a whole variable, aerosol inhalation had no effect on A. baumannii isolation (Appendix Table 4).

In the propensity-matched cohort, the possible glucocorticoid-related covariables were balanced in both groups (Appendix Table 5). Univariate and multivariate Cox regression analyses also indicated that glucocorticoid aerosol therapy was an independent risk factor for A. baumannii isolation (Table 3; Appendix Table 6). In an independent model that included indications for glucocorticoid aerosol therapy, risk factors for A. baumannii isolation were glucocorticoid aerosol treatments for COPD or asthma and for ARDS (Appendix Table 7).

Log-rank analysis showed that the difference among the groups was statistically significant (p<0.001). The cumulative hazard for A. baumannii isolation was significantly higher in the glucocorticoid aerosol group compared with the no aerosol inhalation (HR 1.871; 95% CI 1.206–2.772; p<0.001) and aerosol inhalation without glucocorticoid (HR 2.316; 95% CI 1.482–3.620; p = 0.002) groups (Figure 2).

Effect of Glucocorticoid Aerosol Therapy on A. baumannii Isolation among Subgroups

We divided patients into subgroups to evaluate the contribution of glucocorticoid aerosol to A. baumannii isolation from different subpopulations. We found glucocorticoid aerosol was a promoting factor for A. baumannii isolation from most subpopulations, except patients with type 2 diabetes mellitus, hematologic malignancy, antimicrobial drug use for A. baumannii, and short ICU stays (p>0.05) (Figure 3). We noted no statistically significant interactions between most prespecified subgroups defined by demographics, medical history, underlying conditions, APACHE II score, treatment measures, and length of ICU stay (interaction p>0.05). The favorable effect of glucocorticoid aerosol on A. baumannii isolation was relatively greater in the subgroup of patients with longer vasopressor treatment (interaction p = 0.006) (Figure 3).

Association between Glucocorticoid Aerosol Therapy and Clinical Prognosis

We performed univariate and multivariate Cox regression analyses to evaluate the possible risk factors for 30-day mortality in critically ill patients on ventilators. We found glucocorticoid aerosol was not a risk factor for 30-day mortality in those patients, but A. baumannii isolation was independently associated with 30-day mortality (HR 1.824, 95% CI 1.317–2.104; p = 0.045) (Appendix Tables 8, 9). A further separate analysis of A. baumannii isolation status showed that A. baumannii infection was independently associated with 30-day mortality (HR 2.759, 95% CI 1.575–4.833; p = 0.012) (Appendix Tables 8, 10).


In this study, we assessed the effect of the commonly used glucocorticoid aerosol therapy on the frequency of A. baumannii–positive cultures from lower respiratory tract samples in 3 ICUs in China. After controlling for other variables, our findings showed that glucocorticoid aerosol increased the risk for A. baumannii isolation from critically ill patients on invasive mechanical ventilation.

A. baumannii is ubiquitous in nature and is becoming more frequent in hospitals. In our study, 32% of patients acquired A. baumannii during the 30-day follow-up period. Over the past 2 decades, several studies have attempted to characterize and identify risk factors for A. baumannii colonization or infection. Invasive operations, such as endotracheal mechanical ventilation, inserted invasive devices, ICU stays, recent surgery, use of broad-spectrum antimicrobial drugs, ineffective antimicrobial therapy, and septic shock at diagnosis, are risk factors for MDR A. baumannii colonization or infection and for death (5,3133).

We determined that prolonged use of broad-spectrum antimicrobial drugs, invasive mechanical ventilation, and vasopressor treatment were independent risk factors for A. baumannii isolation from ventilated patients, which is consistent with previous studies (5,3133). A previous study reported that cardiovascular organ failure was an independent risk factor associated with A. baumannii bloodstream infection (34). Of note, model 1 of our study showed that cardiovascular disease also was an independent risk factor for A. baumannii isolation. Another population-based study reported that patients with chronic heart failure had a markedly increased risk for hospitalization with pneumonia (35), indicating a possible correlation between cardiovascular diseases and pneumonia. However, the specific underlying mechanisms by which cardiovascular disease promotes A. baumannii isolation remain unknown.

In critically ill patients undergoing mechanical ventilation, aerosol inhalation is a common intervention for treating various pulmonary diseases. An international survey demonstrated that 99% of 611 ICUs from 70 countries reported using aerosol therapy during mechanical ventilation, including noninvasive ventilation, and the most frequently delivered drugs were bronchodilators and steroids (36). A web-based survey involving 447 hospitals in mainland China recorded a high proportion of aerosol therapy in both invasive (90.8%) and noninvasive (91.3%) mechanical ventilation; bronchodilators (64.8%) and topical corticosteroids (43.4%) were the most commonly used drugs (9). Aerosol inhalation is aimed at reversing bronchoconstriction, decreasing the work of breathing, relieving dyspnea, modifying the inflammatory response (19,37), ameliorating lung injury (38), and reducing the rate of exacerbation in both asthma and COPD. However, in patients with COPD and asthma, inhaled corticosteroids are associated with an increased risk for upper respiratory tract infections (39,40), pneumonia, and lower respiratory tract infections (15,41).

Ventilated patients are already vulnerable to pneumonia. Therefore, evaluating whether commonly used aerosol therapy increases the risk for nosocomial pneumonia is crucial, especially when inhaled with glucocorticoids. Because A. baumanni–related pneumonia is associated with severe illness and death, we chose A. baumannii isolation as an outcome and explored its relationship with glucocorticoid aerosol therapy. Our study showed that glucocorticoid aerosol therapy was an independent risk factor for A. baumannii isolation from patients on ventilators. Compared with no aerosol inhalation, glucocorticoid aerosol inhalation increased the risk for A. baumannii by ≈1.5 times. Although further analysis revealed that glucocorticoid aerosol was not directly associated with 30-day mortality, it still might contribute to poor clinical prognosis due to its effect on A. baumannii isolation. As we described, A. baumannii, especially MDR A. baumannii pneumonia, is well recognized as a risk factor for death. In this study, we also found A. baumannii isolation was an independent risk factor for 30-day mortality in patients receiving invasive mechanical ventilation. Because glucocorticoid aerosol heightened the likelihood of acquiring A. baumannii, it might exert a secondary effect, death among A. baumannii–infected patients. Thus, further investigation in a much larger patient population could describe a downstream mortality effect of glucocorticoid aerosol therapy.

When we included glucocorticoid aerosol indications in multivariate analysis, we found COPD and asthma and possible ARDS were independent risk factors for A. baumannii isolation. Because these structural or underlying lung diseases and severe acute lung injury necessitate longer duration of mechanical ventilation, our results were compatible with previously described risk factors for A. baumannii infection. In contrast to glucocorticoid aerosol, we did not detect an association between aerosol inhalation without glucocorticoid and A. baumannii. Because both therapies generate aerosols, our previous concern that aerosols were a source of A. baumannii acquisition might not be reasonable.

Reasons why glucocorticoids increase the risk for A. baumannii isolation remain elusive. Previously considered sterile, healthy lungs harbor complex and dynamic microbiota communities (42). Pulmonary diseases, such as COPD (43), asthma (44), lung cancer (45), and ARDS (46), cause considerable alteration of lung microbiota. Pneumonia pathogenesis involves an abrupt and emergent disruption in the complex homeostasis of the lung microbial ecosystem (47). A recent study reported that inhaled corticosteroids altered the lung microbiota in both COPD patients and mouse models and impaired bacterial control in models with Streptococcus pneumonia infection (14). Antimicrobial peptides, also known as host defense peptides, are short and generally positively charged peptides that participate in the regulation of the host’s antibacterial actions and immune defense (48). Another study observed that cathelicidin, an antimicrobial peptide, was impaired by inhaled corticosteroids among COPD patients by increasing protease cathepsin D, thereby promoting the proliferation of Streptococcus (14). In a bacterial 16S rRNA gene sequencing and host transcriptomic analysis, another study reported that as COPD severity increased, the airway microbiome becomes associated with decreased abundance of Prevotella bacteria in concert with downregulation of genes promoting epithelial defense associated with inhaled corticosteroid use (49). Evidence also suggests that in asthma, inhaled corticosteroids can alter the relative abundance of genera in airway microbiome (50). Therefore, inhaled corticosteroids play a primary role in lung microbiota disruption and host-defense suppression, which could explain why glucocorticoid aerosol contributed to the increased risk for A. baumannii isolation from patients on ventilators.

Clinicians should individualize patient care and manage treatments on the basis of subgroup analysis results. Our results showed that, in most subpopulations, regardless of the presence or absence of the prespecified characteristics, patients were at higher risk for A. baumannii isolation when receiving glucocorticoid aerosol. Based on our findings, we recommend that intensive care teams more carefully consider the risk of widespread usage of glucocorticoid aerosol in patients with invasive mechanical ventilation. Because glucocorticoid aerosol therapy had a much greater favorable effect on A. baumannii isolation in the subgroup of patients on vasopressors for >3 days, clinicians should be particularly cautious about giving glucocorticoid aerosol to patients on long vasopressor treatments. Because patients with diabetes, hematologic malignancy, and shorter ICU stays were at relatively lower risk for glucocorticoid aerosol–associated A. baumannii acquisition, glucocorticoid aerosol could be considered when appropriate for indications in these patients. Altogether, our study suggests ICU teams need to identify the specific patient subgroups that will truly benefit from glucocorticoid aerosol therapy rather than more generalized administration. Limiting glucocorticoid aerosol use might be considered as part of existing antimicrobial stewardship bundles. In addition, defining the duration of glucocorticoid aerosol therapy might help maximize benefit while reducing associated risk. Interventional studies exploring the effects of different glucocorticoid aerosol therapy durations on the occurrence of various types of nosocomial pneumonia are needed.

The first limitation of our study is that, because it was an observational study, confounders that might influence the effect of glucocorticoid aerosol on A. baumannii isolation remain, even after adjusting by subgroup analysis, propensity score matching analysis, and multivariable Cox regression. A similar situation exists for the analysis of risk factors for death. Second, a potential time bias remains, in which patients might have been exposed to risk factors before study enrollment. However, we have excluded patients with prolonged exposure to several well-known risk factors to minimize the possible effect of time bias. Third, exclusion of certain cases might pose a potential selection bias, including survivorship bias. Future randomized controlled interventional studies are expected to confirm our findings and minimize the effects of confounders and the above biases. Fourth, the study included only 3 ICUs in China and did not focus on pathogens other than A. baumannii. Research involving more centers and more cases could explore whether glucocorticoid aerosol is a common risk factor in the overall nosocomial pneumonia risk.

In conclusion, we found glucocorticoid aerosol therapy was an independent risk factor for A. baumannii isolation from patients receiving invasive mechanical ventilation. Because of high mortality rates associated with A. baumannii–related nosocomial pneumonia, clinicians should carefully consider both the beneficial and harmful effects of glucocorticoid aerosol before administering this therapy.



We thank Oxford Science Editing Ltd. for language editing.

This work was supported by the National Natural Science Foundation of China (grant nos. 81873927, 82072231), Taishan Scholars Program of Shandong Province (award no. tsqn202103165), Clinical Research Center of Shandong University (grant no.2020SDUCRCC013), Natural Science Foundation of Shandong Province (grant no. ZR2020QH021), China Postdoctoral Science Foundation (grant no. 2018M632685), and the Project of Science and Technology of Qingdao People’s Livelihood (grant no. 19-6-1-23-nsh).



  1. Vincent  JL, Rello  J, Marshall  J, Silva  E, Anzueto  A, Martin  CD, et al.; EPIC II Group of Investigators. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302:23239. DOIPubMedGoogle Scholar
  2. Vincent  JL, Sakr  Y, Singer  M, Martin-Loeches  I, Machado  FR, Marshall  JC, et al.; EPIC III Investigators. Prevalence and outcomes of infection among patients in intensive care units in 2017. JAMA. 2020;323:147887. DOIPubMedGoogle Scholar
  3. Mea  HJ, Yong  PVC, Wong  EH. An overview of Acinetobacter baumannii pathogenesis: Motility, adherence and biofilm formation. Microbiol Res. 2021;247:126722. DOIPubMedGoogle Scholar
  4. Lynch  JP III, Zhanel  GG, Clark  NM. Infections due to Acinetobacter baumannii in the ICU: treatment options. Semin Respir Crit Care Med. 2017;38:31125. DOIPubMedGoogle Scholar
  5. Shi  J, Sun  T, Cui  Y, Wang  C, Wang  F, Zhou  Y, et al. Multidrug resistant and extensively drug resistant Acinetobacter baumannii hospital infection associated with high mortality: a retrospective study in the pediatric intensive care unit. BMC Infect Dis. 2020;20:597. DOIPubMedGoogle Scholar
  6. Sunenshine  RH, Wright  MO, Maragakis  LL, Harris  AD, Song  X, Hebden  J, et al. Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis. 2007;13:97103. DOIPubMedGoogle Scholar
  7. Blanco  N, Harris  AD, Rock  C, Johnson  JK, Pineles  L, Bonomo  RA, et al.; the CDC Epicenters Program. Risk factors and outcomes associated with multidrug-resistant Acinetobacter baumannii upon intensive care unit admission. Antimicrob Agents Chemother. 2017;62:e0163117.PubMedGoogle Scholar
  8. Zhang  C, Mi  J, Wang  X, Lv  S, Zhang  Z, Nie  Z, et al. Knowledge and current practices of ICU nurses regarding aerosol therapy for patients treated with invasive mechanical ventilation: A nationwide cross-sectional study. J Clin Nurs. 2021;30:342938. DOIPubMedGoogle Scholar
  9. Zhang  Z, Xu  P, Fang  Q, Ma  P, Lin  H, Fink  JB, et al.; China Union of Respiratory Care (CURC). Practice pattern of aerosol therapy among patients undergoing mechanical ventilation in mainland China: A web-based survey involving 447 hospitals. PLoS One. 2019;14:e0221577. DOIPubMedGoogle Scholar
  10. Lyu  S, Li  J, Wu  M, He  D, Fu  T, Ni  F, et al.; Respiratory Care Committee in Chinese Thoracic Society. The use of aerosolized medications in adult intensive care unit patients: A prospective, multicenter, observational, cohort Study. J Aerosol Med Pulm Drug Deliv. 2021;34:38391. DOIPubMedGoogle Scholar
  11. Lyu  S, Li  J, Yang  L, Du  X, Liu  X, Chuan  L, et al. The utilization of aerosol therapy in mechanical ventilation patients: a prospective multicenter observational cohort study and a review of the current evidence. Ann Transl Med. 2020;8:1071. DOIPubMedGoogle Scholar
  12. Dhand  R. Inhaled drug therapy 2016: the year in review. Respir Care. 2017;62:97896. DOIPubMedGoogle Scholar
  13. Ari  A. Practical strategies for a safe and effective delivery of aerosolized medications to patients with COVID-19. Respir Med. 2020;167:105987. DOIPubMedGoogle Scholar
  14. Singanayagam  A, Glanville  N, Cuthbertson  L, Bartlett  NW, Finney  LJ, Turek  E, et al. Inhaled corticosteroid suppression of cathelicidin drives dysbiosis and bacterial infection in chronic obstructive pulmonary disease. Sci Transl Med. 2019;11:eaav3879. DOIPubMedGoogle Scholar
  15. Ernst  P, Gonzalez  AV, Brassard  P, Suissa  S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med. 2007;176:1626. DOIPubMedGoogle Scholar
  16. Sibila  O, Soto-Gomez  N, Restrepo  MI. The risk and outcomes of pneumonia in patients on inhaled corticosteroids. Pulm Pharmacol Ther. 2015;32:1306. DOIPubMedGoogle Scholar
  17. Artigas  A, Camprubí-Rimblas  M, Tantinyà  N, Bringué  J, Guillamat-Prats  R, Matthay  MA. Inhalation therapies in acute respiratory distress syndrome. Ann Transl Med. 2017;5:293. DOIPubMedGoogle Scholar
  18. van Rensen  EL, Straathof  KC, Veselic-Charvat  MA, Zwinderman  AH, Bel  EH, Sterk  PJ. Effect of inhaled steroids on airway hyperresponsiveness, sputum eosinophils, and exhaled nitric oxide levels in patients with asthma. Thorax. 1999;54:4038. DOIPubMedGoogle Scholar
  19. Horvath  G, Wanner  A. Inhaled corticosteroids: effects on the airway vasculature in bronchial asthma. Eur Respir J. 2006;27:17287. DOIPubMedGoogle Scholar
  20. Leading Industry Research Network. Analysis on market demand status and market development trend of budesonide inhalation preparations in China in 2020. 2020 Nov 23 [cited 2022 Jan 24].
  21. Gales  AC, Seifert  H, Gur  D, Castanheira  M, Jones  RN, Sader  HS. Antimicrobial susceptibility of Acinetobacter calcoaceticus-Acinetobacter baumannii complex and Stenotrophomonas maltophilia clinical isolates: results from the SENTRY antimicrobial surveillance program (1997–2016). Open Forum Infect Dis. 2019;6(Suppl 1):S3446. DOIPubMedGoogle Scholar
  22. European Centre for Disease Prevention and Control. Surveillance of antimicrobial resistance in Europe 2018. Stockholm: The Centre; 2019.
  23. Hu  F, Guo  Y, Zhu  D, Wang  F, Jiang  X, Xu  Y, et al. CHINET surveillance of bacterial resistance in China: 2018 report. Chin J Infect Chemother. 2020;20:110.
  24. Wang  F, Zhu  D, Hu  F, Jiang  X, Hu  Z, Li  Q, et al. 2012 CHINET surveillance of bacterial resistance in China. Chin J Infect Chemother. 2013;13:32130.
  25. Meng  X, Fu  J, Zheng  Y, Qin  W, Yang  H, Cao  D, et al. Ten-year changes in bloodstream infection with Acinetobacter baumannii complex in intensive care units in eastern China: a retrospective cohort study. Front Med (Lausanne). 2021;8:715213. DOIPubMedGoogle Scholar
  26. Chung  DR, Song  JH, Kim  SH, Thamlikitkul  V, Huang  SG, Wang  H, et al.; Asian Network for Surveillance of Resistant Pathogens Study Group. High prevalence of multidrug-resistant nonfermenters in hospital-acquired pneumonia in Asia. Am J Respir Crit Care Med. 2011;184:140917. DOIPubMedGoogle Scholar
  27. Xie  J, Yang  Y, Huang  Y, Kang  Y, Xu  Y, Ma  X, et al. The current epidemiological landscape of ventilator-associated pneumonia in the intensive care unit: a multicenter prospective observational study in China. Clin Infect Dis. 2018;67(suppl_2):S15361. DOIPubMedGoogle Scholar
  28. Hu  FP, Guo  Y, Zhu  DM, Wang  F, Jiang  XF, Xu  YC, et al. Resistance trends among clinical isolates in China reported from CHINET surveillance of bacterial resistance, 2005-2014. Clin Microbiol Infect. 2016;22(Suppl 1):S914. DOIPubMedGoogle Scholar
  29. Hu  F, Guo  Y, Yang  Y, Zheng  Y, Wu  S, Jiang  X, et al.; China Antimicrobial Surveillance Network (CHINET) Study Group. Resistance reported from China antimicrobial surveillance network (CHINET) in 2018. Eur J Clin Microbiol Infect Dis. 2019;38:227581. DOIPubMedGoogle Scholar
  30. Huang  H, Chen  B, Liu  G, Ran  J, Lian  X, Huang  X, et al. A multi-center study on the risk factors of infection caused by multi-drug resistant Acinetobacter baumannii. BMC Infect Dis. 2018;18:11. DOIPubMedGoogle Scholar
  31. Bassetti  M, Righi  E, Vena  A, Graziano  E, Russo  A, Peghin  M. Risk stratification and treatment of ICU-acquired pneumonia caused by multidrug- resistant/extensively drug-resistant/pandrug-resistant bacteria. Curr Opin Crit Care. 2018;24:38593. DOIPubMedGoogle Scholar
  32. Freire  MP, de Oliveira Garcia  D, Garcia  CP, Campagnari Bueno  MF, Camargo  CH, Kono Magri  ASG, et al. Bloodstream infection caused by extensively drug-resistant Acinetobacter baumannii in cancer patients: high mortality associated with delayed treatment rather than with the degree of neutropenia. Clin Microbiol Infect. 2016;22:3528. DOIPubMedGoogle Scholar
  33. Yamada  K, Yanagihara  K, Araki  N, Harada  Y, Morinaga  Y, Akamatsu  N, et al. Clinical characteristics of tertiary hospital patients from whom Acinetobacter calcoaceticus-Acinetobacter baumannii complex strains were isolated. Intern Med. 2012;51:517. DOIPubMedGoogle Scholar
  34. Jang  TN, Lee  SH, Huang  CH, Lee  CL, Chen  WY. Risk factors and impact of nosocomial Acinetobacter baumannii bloodstream infections in the adult intensive care unit: a case-control study. J Hosp Infect. 2009;73:14350. DOIPubMedGoogle Scholar
  35. Mor  A, Thomsen  RW, Ulrichsen  SP, Sørensen  HT. Chronic heart failure and risk of hospitalization with pneumonia: a population-based study. Eur J Intern Med. 2013;24:34953. DOIPubMedGoogle Scholar
  36. Ehrmann  S, Roche-Campo  F, Sferrazza Papa  GF, Isabey  D, Brochard  L, Apiou-Sbirlea  G; REVA research network. Aerosol therapy during mechanical ventilation: an international survey. Intensive Care Med. 2013;39:104856. DOIPubMedGoogle Scholar
  37. Hashemian  SM, Mortaz  E, Jamaati  H, Bagheri  L, Mohajerani  SA, Garssen  J, et al. Budesonide facilitates weaning from mechanical ventilation in difficult-to-wean very severe COPD patients: Association with inflammatory mediators and cells. J Crit Care. 2018;44:1617. DOIPubMedGoogle Scholar
  38. Ju  YN, Yu  KJ, Wang  GN. Budesonide ameliorates lung injury induced by large volume ventilation. BMC Pulm Med. 2016;16:90. DOIPubMedGoogle Scholar
  39. Yang  M, Zhang  Y, Chen  H, Lin  J, Zeng  J, Xu  Z. Inhaled corticosteroids and risk of upper respiratory tract infection in patients with asthma: a meta-analysis. Infection. 2019;47:37785. DOIPubMedGoogle Scholar
  40. Yang  M, Chen  H, Zhang  Y, Du  Y, Xu  Y, Jiang  P, et al. Long-term use of inhaled corticosteroids and risk of upper respiratory tract infection in chronic obstructive pulmonary disease: a meta-analysis. Inhal Toxicol. 2017;29:21926. DOIPubMedGoogle Scholar
  41. McKeever  T, Harrison  TW, Hubbard  R, Shaw  D. Inhaled corticosteroids and the risk of pneumonia in people with asthma: a case-control study. Chest. 2013;144:178894. DOIPubMedGoogle Scholar
  42. Wang  J, Li  F, Tian  Z. Role of microbiota on lung homeostasis and diseases. Sci China Life Sci. 2017;60:140715. DOIPubMedGoogle Scholar
  43. Sze  MA, Dimitriu  PA, Hayashi  S, Elliott  WM, McDonough  JE, Gosselink  JV, et al. The lung tissue microbiome in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;185:107380. DOIPubMedGoogle Scholar
  44. Hilty  M, Burke  C, Pedro  H, Cardenas  P, Bush  A, Bossley  C, et al. Disordered microbial communities in asthmatic airways. PLoS One. 2010;5:e8578. DOIPubMedGoogle Scholar
  45. Laroumagne  S, Lepage  B, Hermant  C, Plat  G, Phelippeau  M, Bigay-Game  L, et al. Bronchial colonisation in patients with lung cancer: a prospective study. Eur Respir J. 2013;42:2209. DOIPubMedGoogle Scholar
  46. Dickson  RP, Singer  BH, Newstead  MW, Falkowski  NR, Erb-Downward  JR, Standiford  TJ, et al. Enrichment of the lung microbiome with gut bacteria in sepsis and the acute respiratory distress syndrome. Nat Microbiol. 2016;1:16113. DOIPubMedGoogle Scholar
  47. Dickson  RP, Erb-Downward  JR, Huffnagle  GB. Towards an ecology of the lung: new conceptual models of pulmonary microbiology and pneumonia pathogenesis. Lancet Respir Med. 2014;2:23846. DOIPubMedGoogle Scholar
  48. Lai  Y, Gallo  RL. AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense. Trends Immunol. 2009;30:13141. DOIPubMedGoogle Scholar
  49. Ramsheh  MY, Haldar  K, Esteve-Codina  A, Purser  LF, Richardson  M, Müller-Quernheim  J, et al. Lung microbiome composition and bronchial epithelial gene expression in patients with COPD versus healthy individuals: a bacterial 16S rRNA gene sequencing and host transcriptomic analysis. Lancet Microbe. 2021;2:e30010. DOIPubMedGoogle Scholar
  50. Huang  C, Yu  Y, Du  W, Liu  Y, Dai  R, Tang  W, et al. Fungal and bacterial microbiome dysbiosis and imbalance of trans-kingdom network in asthma. Clin Transl Allergy. 2020;10:42. DOIPubMedGoogle Scholar




Follow Up

Earning CME Credit

To obtain credit, you should first read the journal article. After reading the article, you should be able to answer the following, related, multiple-choice questions. To complete the questions (with a minimum 75% passing score) and earn continuing medical education (CME) credit, please go to Credit cannot be obtained for tests completed on paper, although you may use the worksheet below to keep a record of your answers.

You must be a registered user on If you are not registered on, please click on the “Register” link on the right hand side of the website.

Only one answer is correct for each question. Once you successfully answer all post-test questions, you will be able to view and/or print your certificate. For questions regarding this activity, contact the accredited provider, For technical assistance, contact American Medical Association’s Physician’s Recognition Award (AMA PRA) credits are accepted in the US as evidence of participation in CME activities. For further information on this award, please go to The AMA has determined that physicians not licensed in the US who participate in this CME activity are eligible for AMA PRA Category 1 Credits™. Through agreements that the AMA has made with agencies in some countries, AMA PRA credit may be acceptable as evidence of participation in CME activities. If you are not licensed in the US, please complete the questions online, print the AMA PRA CME credit certificate, and present it to your national medical association for review.

Article Title: 
Acinetobacter baumannii among Patients Receiving Glucocorticoid Aerosol Therapy during Invasive Mechanical Ventilation, China
CME Questions
  • What was the rate of isolation of Acinetobacter baumannii (AB) from patients with invasive mechanical ventilation (IMV) in the current study by Zhang and colleagues?

    • 4%

    • 9%

    • 32%

    • 54%

  • Which of the following statements regarding the role of aerosol inhalation in the isolation of AB in the current study is most accurate?

    • Any aerosol inhalation during IMV was associated with a higher risk for AB

    • Only aerosol inhalation with corticosteroids during IMV was associated with a higher risk for AB

    • Aerosol inhalation during IMV did not significantly affect the risk for AB

    • Aerosol inhalation with corticosteroids during IMV was associated with a lower risk for AB

  • Which of the following was the LEAST significant risk factor for AB in the current study?

    • Aerosol inhalation with glucocorticoids (AIG)

    • Being a current or former smoker

    • IMV for ≥ 5 days

    • Use of a broad-spectrum antibiotic for ≥ 7 days

  • Which of the following statements regarding risk factors for 30-day mortality in the current study is most accurate?

    • Any inhalation therapy was associated with a higher risk for mortality

    • Only inhalation therapy with corticosteroids was associated with a higher risk for mortality

    • Inhalation therapy with or without corticosteroids was not associated with a higher risk for mortality

    • AB was not associated with a higher risk for mortality


Cite This Article

DOI: 10.3201/eid2812.220347

1These authors contributed equally to this article.

Related Links

Table of Contents – Volume 28, Number 12—December 2022

EID Search Options
presentation_01 Advanced Article Search – Search articles by author and/or keyword.
presentation_01 Articles by Country Search – Search articles by the topic country.
presentation_01 Article Type Search – Search articles by article type and issue.



Please use the form below to submit correspondence to the authors or contact them at the following address:

Hao Wang, Department of Critical Care Medicine, Qilu Hospital of Shandong University, 107 Wenhuaxi Rd, Jinan 250012, China

Send To

10000 character(s) remaining.


Page created: October 17, 2022
Page updated: November 17, 2022
Page reviewed: November 17, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.